Cellular senescence |
160 |
11.8 |
33 |
4.00E-08 |
1.27E-05 |
HTLV-I infection |
219 |
16.1 |
38 |
4.51E-07 |
6.97E-05 |
FoxO signaling pathway |
132 |
9.71 |
27 |
8.29E-07 |
6.97E-05 |
TNF signaling pathway |
110 |
8.09 |
24 |
1.00E-06 |
6.97E-05 |
Chagas disease (American trypanosomiasis) |
103 |
7.57 |
23 |
1.10E-06 |
6.97E-05 |
Kaposi’s sarcoma-associated herpesvirus infection |
186 |
13.7 |
33 |
1.57E-06 |
8.32E-05 |
Pathways in cancer |
530 |
39 |
67 |
5.56E-06 |
0.000253 |
Renal cell carcinoma |
69 |
5.07 |
17 |
6.86E-06 |
0.000273 |
Colorectal cancer |
86 |
6.32 |
18 |
4.10E-05 |
0.00138 |
Complement and coagulation cascades |
79 |
5.81 |
17 |
4.60E-05 |
0.00138 |
p53 signaling pathway |
72 |
5.3 |
16 |
5.06E-05 |
0.00138 |
Apelin signaling pathway |
137 |
10.1 |
24 |
5.19E-05 |
0.00138 |
Insulin resistance |
108 |
7.94 |
20 |
9.79E-05 |
0.00239 |
MAPK signaling pathway |
295 |
21.7 |
40 |
0.000105 |
0.00239 |
mTOR signaling pathway |
153 |
11.3 |
25 |
0.000118 |
0.00239 |
IL-17 signaling pathway |
93 |
6.84 |
18 |
0.00012 |
0.00239 |
Hepatitis B |
163 |
12 |
26 |
0.000131 |
0.00245 |
cAMP signaling pathway |
212 |
15.6 |
31 |
0.000161 |
0.00285 |
cGMP-PKG signaling pathway |
166 |
12.2 |
26 |
0.000177 |
0.00297 |
Circadian rhythm |
31 |
2.28 |
9 |
0.000274 |
0.00436 |
Oxytocin signaling pathway |
153 |
11.3 |
24 |
0.000305 |
0.00451 |
AGE-RAGE signaling pathway in diabetic complications |
100 |
7.35 |
18 |
0.000312 |
0.00451 |
Proteoglycans in cancer |
201 |
14.8 |
29 |
0.000329 |
0.00455 |
Chronic myeloid leukemia |
76 |
5.59 |
15 |
0.00035 |
0.00464 |
Sphingolipid signaling pathway |
119 |
8.75 |
20 |
0.000382 |
0.00485 |
Breast cancer |
147 |
10.8 |
23 |
0.00042 |
0.00514 |
B cell receptor signaling pathway |
71 |
5.22 |
14 |
0.000553 |
0.00651 |
Prostate cancer |
97 |
7.13 |
17 |
0.000627 |
0.00691 |
Melanoma |
72 |
5.3 |
14 |
0.000641 |
0.00691 |
Platelet activation |
124 |
9.12 |
20 |
0.000661 |
0.00691 |
Longevity regulating pathway |
89 |
6.55 |
16 |
0.000673 |
0.00691 |
Mitophagy - animal |
65 |
4.78 |
13 |
0.00075 |
0.00746 |
Ras signaling pathway |
232 |
17.1 |
31 |
8.00E-04 |
0.00771 |
Rheumatoid arthritis |
91 |
6.69 |
16 |
0.000866 |
0.008 |
Apoptosis |
136 |
10 |
21 |
0.000881 |
0.008 |
Pancreatic cancer |
75 |
5.52 |
14 |
0.00098 |
0.00842 |
Glioma |
75 |
5.52 |
14 |
0.00098 |
0.00842 |
Neurotrophin signaling pathway |
119 |
8.75 |
19 |
0.00101 |
0.00848 |
Small cell lung cancer |
93 |
6.84 |
16 |
0.0011 |
0.00892 |
Pertussis |
76 |
5.59 |
14 |
0.00112 |
0.00892 |
Epithelial cell signaling in Helicobacter pylori infection |
68 |
5 |
13 |
0.00117 |
0.00907 |
Legionellosis |
55 |
4.04 |
11 |
0.00188 |
0.014 |
Th17 cell differentiation |
107 |
7.87 |
17 |
0.00194 |
0.014 |
Regulation of actin cytoskeleton |
214 |
15.7 |
28 |
0.00194 |
0.014 |
Phosphatidylinositol signaling system |
99 |
7.28 |
16 |
0.00217 |
0.015 |
Choline metabolism in cancer |
99 |
7.28 |
16 |
0.00217 |
0.015 |
Rap1 signaling pathway |
206 |
15.1 |
27 |
0.00226 |
0.0153 |
Insulin signaling pathway |
137 |
10.1 |
20 |
0.00232 |
0.0154 |
Non-small cell lung cancer |
66 |
4.85 |
12 |
0.00279 |
0.018 |
Focal adhesion |
199 |
14.6 |
26 |
0.00283 |
0.018 |
Endometrial cancer |
58 |
4.27 |
11 |
0.00293 |
0.0183 |
Chemokine signaling pathway |
190 |
14 |
25 |
0.00308 |
0.0188 |
Prion diseases |
35 |
2.57 |
8 |
0.00324 |
0.0195 |
ErbB signaling pathway |
85 |
6.25 |
14 |
0.00336 |
0.0198 |
Salmonella infection |
86 |
6.32 |
14 |
0.00376 |
0.0217 |
Adipocytokine signaling pathway |
69 |
5.07 |
12 |
0.00408 |
0.023 |
Amoebiasis |
96 |
7.06 |
15 |
0.00412 |
0.023 |
EGFR tyrosine kinase inhibitor resistance |
79 |
5.81 |
13 |
0.00468 |
0.0256 |
Cytokine-cytokine receptor interaction |
294 |
21.6 |
34 |
0.00532 |
0.0287 |
Wnt signaling pathway |
158 |
11.6 |
21 |
0.00569 |
0.0297 |
Measles |
138 |
10.1 |
19 |
0.00569 |
0.0297 |
HIF-1 signaling pathway |
100 |
7.35 |
15 |
0.00607 |
0.0306 |
Inflammatory mediator regulation of TRP channels |
100 |
7.35 |
15 |
0.00607 |
0.0306 |
Fluid shear stress and atherosclerosis |
139 |
10.2 |
19 |
0.00615 |
0.0306 |
PI3K-Akt signaling pathway |
354 |
26 |
39 |
0.00673 |
0.0329 |
Cholinergic synapse |
112 |
8.24 |
16 |
0.00754 |
0.0362 |
GnRH signaling pathway |
93 |
6.84 |
14 |
0.00764 |
0.0362 |
Vascular smooth muscle contraction |
132 |
9.71 |
18 |
0.00774 |
0.0362 |
Glucagon signaling pathway |
103 |
7.57 |
15 |
0.00799 |
0.0368 |
Malaria |
49 |
3.6 |
9 |
0.00853 |
0.0387 |
Fc epsilon RI signaling pathway |
68 |
5 |
11 |
0.0101 |
0.0448 |
Amphetamine addiction |
68 |
5 |
11 |
0.0101 |
0.0448 |
Pantothenate and CoA biosynthesis |
19 |
1.4 |
5 |
0.0103 |
0.045 |
Aldosterone synthesis and secretion |
98 |
7.21 |
14 |
0.012 |
0.0505 |
Estrogen signaling pathway |
138 |
10.1 |
18 |
0.0121 |
0.0505 |
Autophagy - animal |
128 |
9.41 |
17 |
0.0122 |
0.0505 |
Osteoclast differentiation |
128 |
9.41 |
17 |
0.0122 |
0.0505 |
Prolactin signaling pathway |
70 |
5.15 |
11 |
0.0125 |
0.0511 |
Signaling pathways regulating pluripotency of stem cells |
139 |
10.2 |
18 |
0.013 |
0.0522 |
Axon guidance |
181 |
13.3 |
22 |
0.0132 |
0.0524 |
Longevity regulating pathway - multiple species |
62 |
4.56 |
10 |
0.0142 |
0.0554 |
AMPK signaling pathway |
120 |
8.83 |
16 |
0.0143 |
0.0554 |
T cell receptor signaling pathway |
101 |
7.43 |
14 |
0.0154 |
0.0584 |
Melanogenesis |
101 |
7.43 |
14 |
0.0154 |
0.0584 |
Thyroid cancer |
37 |
2.72 |
7 |
0.0166 |
0.0623 |
Transcriptional misregulation in cancer |
186 |
13.7 |
22 |
0.0177 |
0.0654 |
Leishmaniasis |
74 |
5.44 |
11 |
0.0186 |
0.068 |
Adrenergic signaling in cardiomyocytes |
145 |
10.7 |
18 |
0.0194 |
0.0694 |
Central carbon metabolism in cancer |
65 |
4.78 |
10 |
0.0194 |
0.0694 |
Epstein-Barr virus infection |
201 |
14.8 |
23 |
0.0222 |
0.0783 |
Phospholipase D signaling pathway |
148 |
10.9 |
18 |
0.0234 |
0.0817 |
Hematopoietic cell lineage |
97 |
7.13 |
13 |
0.0247 |
0.0855 |
Gap junction |
88 |
6.47 |
12 |
0.0268 |
0.0917 |
Bladder cancer |
41 |
3.02 |
7 |
0.0282 |
0.0955 |
Progesterone-mediated oocyte maturation |
99 |
7.28 |
13 |
0.0287 |
0.0962 |
Dopaminergic synapse |
131 |
9.63 |
16 |
0.0303 |
0.1 |
NF-kappa B signaling pathway |
100 |
7.35 |
13 |
0.0309 |
0.101 |
Hippo signaling pathway |
154 |
11.3 |
18 |
0.0332 |
0.108 |
Leukocyte transendothelial migration |
112 |
8.24 |
14 |
0.0346 |
0.111 |
Fatty acid biosynthesis |
18 |
1.32 |
4 |
0.0387 |
0.123 |
Platinum drug resistance |
73 |
5.37 |
10 |
0.04 |
0.126 |
Toll-like receptor signaling pathway |
104 |
7.65 |
13 |
0.0408 |
0.127 |
Thyroid hormone signaling pathway |
116 |
8.53 |
14 |
0.0447 |
0.138 |
Non-alcoholic fatty liver disease (NAFLD) |
149 |
11 |
17 |
0.046 |
0.14 |
Hypertrophic cardiomyopathy (HCM) |
85 |
6.25 |
11 |
0.0461 |
0.14 |
Shigellosis |
65 |
4.78 |
9 |
0.0471 |
0.141 |